176 related articles for article (PubMed ID: 17909797)
1. Impact of the CCR5 gene polymorphism on the survival of metastatic melanoma patients receiving immunotherapy.
Ugurel S; Schrama D; Keller G; Schadendorf D; Bröcker EB; Houben R; Zapatka M; Fink W; Kaufman HL; Becker JC
Cancer Immunol Immunother; 2008 May; 57(5):685-91. PubMed ID: 17909797
[TBL] [Abstract][Full Text] [Related]
2. Association analysis and allelic distribution of deletion in CC chemokine receptor 5 gene (CCR5Δ32) among breast cancer patients of Pakistan.
Fatima F; Saleem S; Hameed A; Haider G; Ali Zaidi SA; Kanwal M; Zehra S; Azhar A
Mol Biol Rep; 2019 Apr; 46(2):2387-2394. PubMed ID: 30848448
[TBL] [Abstract][Full Text] [Related]
3. No Association between the CCR5Δ32 Polymorphism and Sporadic Esophageal Cancer in Punjab, North-West India.
Sambyal V; Manjari M; Sudan M; Uppal MS; Singh NR; Singh H; Guleria K
Asian Pac J Cancer Prev; 2015; 16(10):4291-5. PubMed ID: 26028088
[TBL] [Abstract][Full Text] [Related]
4. Role of CCR5Δ32 mutation in protecting patients with Schistosoma mansoni infection against hepatitis C viral infection or progression.
El-Moamly AA; El-Sweify MA; Rashad RM; Abdalla EM; Ragheb MM; Awad MM
Parasitol Res; 2013 Jul; 112(7):2745-52. PubMed ID: 23515570
[TBL] [Abstract][Full Text] [Related]
5. CCR5Δ32 (rs333) polymorphism is associated with the susceptibility to systemic lupus erythematosus in female Brazilian patients.
Baltus TH; Kallaur AP; Lozovoy MA; Morimoto HK; Delongui F; Alfieri DF; Iriyoda TM; Dichi I; Simão AN; Reiche EM
Rheumatol Int; 2016 Jan; 36(1):7-15. PubMed ID: 26071874
[TBL] [Abstract][Full Text] [Related]
6. The effect of chemokine receptor gene polymorphisms (CCR2V64I, CCR5-59029G>A and CCR5Δ32) on renal allograft survival in Pakistani transplant patients.
Firasat S; Raza A; Abid A; Aziz T; Mubarak M; Naqvi SA; Rizvi SA; Mehdi SQ; Khaliq S
Gene; 2012 Dec; 511(2):314-9. PubMed ID: 23041556
[TBL] [Abstract][Full Text] [Related]
7. CC chemokine receptor 5 and renal-transplant survival.
Fischereder M; Luckow B; Hocher B; Wüthrich RP; Rothenpieler U; Schneeberger H; Panzer U; Stahl RA; Hauser IA; Budde K; Neumayer H; Krämer BK; Land W; Schlöndorff D
Lancet; 2001 Jun; 357(9270):1758-61. PubMed ID: 11403814
[TBL] [Abstract][Full Text] [Related]
8. Association of heterozygous CCR5Δ32 deletion with survival in HIV-infection: A cohort study.
Ruiz-Mateos E; Tarancon-Diez L; Alvarez-Rios AI; Dominguez-Molina B; Genebat M; Pulido I; Abad MA; Muñoz-Fernandez MA; Leal M
Antiviral Res; 2018 Feb; 150():15-19. PubMed ID: 29221798
[TBL] [Abstract][Full Text] [Related]
9. CCR5Delta32 polymorphism effects on CCR5 expression, patterns of immunopathology and disease course in multiple sclerosis.
Kantarci OH; Morales Y; Ziemer PA; Hebrink DD; Mahad DJ; Atkinson EJ; Achenbach SJ; De Andrade M; Mack M; Ransohoff RM; Lassmann H; Bruck W; Weinshenker BG; Lucchinetti CF
J Neuroimmunol; 2005 Dec; 169(1-2):137-43. PubMed ID: 16182378
[TBL] [Abstract][Full Text] [Related]
10. The clinical significance of adenomatous polyposis coli (APC) and catenin Beta 1 (CTNNB1) genetic aberrations in patients with melanoma.
Karachaliou GS; Alkallas R; Carroll SB; Caressi C; Zakria D; Patel NM; Trembath DG; Ezzell JA; Pegna GJ; Googe PB; Galeotti JP; Ayvali F; Collichio FA; Lee CB; Ollila DW; Gulley ML; Johnson DB; Kim KB; Watson IR; Moschos SJ
BMC Cancer; 2022 Jan; 22(1):38. PubMed ID: 34986841
[TBL] [Abstract][Full Text] [Related]
11. CCR5 deletion mutation and its association with the risk of developing acute graft-versus-host disease after allogeneic hematopoietic stem cell transplantation.
Bogunia-Kubik K; Duda D; Suchnicki K; Lange A
Haematologica; 2006 Dec; 91(12):1628-34. PubMed ID: 17145599
[TBL] [Abstract][Full Text] [Related]
12. Upfront Surgical Resection of Melanoma Brain Metastases Provides a Bridge Toward Immunotherapy-Mediated Systemic Control.
Alvarez-Breckenridge C; Giobbie-Hurder A; Gill CM; Bertalan M; Stocking J; Kaplan A; Nayyar N; Lawrence DP; Flaherty KT; Shih HA; Oh K; Batchelor TT; Cahill DP; Sullivan R; Brastianos PK
Oncologist; 2019 May; 24(5):671-679. PubMed ID: 30796152
[TBL] [Abstract][Full Text] [Related]
13. Prevalence of CCR5Delta32 polymorphism in long-term survivors of heart transplantation.
Hummel M; Bara C; Hirt S; Haverich A; Hetzer R
Transpl Immunol; 2007 Apr; 17(3):223-6. PubMed ID: 17331851
[TBL] [Abstract][Full Text] [Related]
14. Disparities of Immunotherapy Utilization in Patients with Stage III Cutaneous Melanoma: A National Perspective.
Al-Qurayshi Z; Crowther JE; Hamner JB; Ducoin C; Killackey MT; Kandil E
Anticancer Res; 2018 May; 38(5):2897-2901. PubMed ID: 29715114
[TBL] [Abstract][Full Text] [Related]
15. Association Between NRAS and BRAF Mutational Status and Melanoma-Specific Survival Among Patients With Higher-Risk Primary Melanoma.
Thomas NE; Edmiston SN; Alexander A; Groben PA; Parrish E; Kricker A; Armstrong BK; Anton-Culver H; Gruber SB; From L; Busam KJ; Hao H; Orlow I; Kanetsky PA; Luo L; Reiner AS; Paine S; Frank JS; Bramson JI; Marrett LD; Gallagher RP; Zanetti R; Rosso S; Dwyer T; Cust AE; Ollila DW; Begg CB; Berwick M; Conway K;
JAMA Oncol; 2015 Jun; 1(3):359-68. PubMed ID: 26146664
[TBL] [Abstract][Full Text] [Related]
16. Donor CCR5 Delta32 polymorphism and outcome following cardiac transplantation.
Fildes JE; Walker AH; Howlett R; Bittar MN; Hutchinson IV; Leonard CT; Yonan N
Transplant Proc; 2005 Jun; 37(5):2247-9. PubMed ID: 15964389
[TBL] [Abstract][Full Text] [Related]
17. CC chemokine receptor 5delta32 polymorphism-a risk factor for ischemic-type biliary lesions following orthotopic liver transplantation.
Moench C; Uhrig A; Lohse AW; Otto G
Liver Transpl; 2004 Mar; 10(3):434-9. PubMed ID: 15004773
[TBL] [Abstract][Full Text] [Related]
18. Clinicopathological features and clinical outcomes associated with TP53 and BRAF
Kim DW; Haydu LE; Joon AY; Bassett RL; Siroy AE; Tetzlaff MT; Routbort MJ; Amaria RN; Wargo JA; McQuade JL; Kemnade J; Hwu P; Woodman SE; Roszik J; Kim KB; Gershenwald JE; Lazar AJ; Davies MA
Cancer; 2017 Apr; 123(8):1372-1381. PubMed ID: 27911979
[TBL] [Abstract][Full Text] [Related]
19. Systemic treatments for metastatic cutaneous melanoma.
Pasquali S; Hadjinicolaou AV; Chiarion Sileni V; Rossi CR; Mocellin S
Cochrane Database Syst Rev; 2018 Feb; 2(2):CD011123. PubMed ID: 29405038
[TBL] [Abstract][Full Text] [Related]
20. CCR2-64I polymorphism and CCR5Delta32 deletion in patients with Alzheimer's disease.
Galimberti D; Fenoglio C; Lovati C; Gatti A; Guidi I; Venturelli E; Cutter GR; Mariani C; Forloni G; Pettenati C; Baron P; Conti G; Bresolin N; Scarpini E
J Neurol Sci; 2004 Oct; 225(1-2):79-83. PubMed ID: 15465089
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
